454 Life Sciences was a biotechnology company based in Branford, Connecticut that specialized in high-throughput DNA sequencing. It was acquired by Roche in 2007 and shut down by Roche in 2013 when its technology became noncompetitive, although production continued until mid-2016. History ...
(Roche 454 Life Sciences Emulsion-PCR) 기술은 가장 긴 리드(reads)을 생성하는 2세대 시퀀싱 방법이다 (200에서 1000b까지)(Margulies et al., 2005). 454 시퀀싱은 2005년 Roche社가 개발한 최초의 성공적인...
Research outputs, collaborations and relationships for 454 Life Sciences
(non-admin closure) Mediran (t • c) 07:29, 27 March 2013 (UTC) 454 Life Sciences[edit] 454 Life Sciences (edit | talk | history | protect | delete | links | watch | logs | views)...
Abstract Background In this study, we addressed whether a single 454 Life Science GS20 sequencing run provides new gene discovery from a normalized cDNA...
454 Life Sciences는 코네티컷주 브랜포드에 본사를 둔 생명공학 회사로 처리량이 높은 DNA 염기서열 분석을 전문으로 했습니다.2007년 Roche에 인수되어 2013년 Roche에 의해 폐쇄되었으며, 생산은 2016년 중반까지 계속되었다.454 생명과학은 조나단 로스버그에 의해 설립되었으며 원래 CuraGen의 자회사 454
Roche is taking another step toward reducing its focus on gene sequencing by shutting down 454 Life Sciences, a subsidiary in the space it acquired from Curagen more than 6 years ago for $155 million.
Abstract Background In this study, we addressed whether a single 454 Life Science GS20 sequencing run provides new gene discovery from a normalized cDNA library, and whether the short reads produce...
In 2005, 454 Life Sciences launched the first next-generation DNA sequencer – a big leap forward in DNA sequencing technology that made it possible to sequence many samples simultaneously.
Max Planck Institute for Evolutionary Anthropology and 454 Life Sciences Corporation unveil plan to sequence the Neandertal Genome